Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.28 USD
Change Today -0.0027 / -0.95%
Volume 236.3K
LPTN On Other Exchanges
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (LPTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/14 - $4.19
52 Week Low
05/28/15 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LPATH INC-CLASS A (LPTN)

Related News

No related news articles were found.

lpath inc-class a (LPTN) Related Businessweek News

No Related Businessweek News Found

lpath inc-class a (LPTN) Details

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. The company is developing iSONEP, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and is in Phase Ib/IIa clinical trials to treat retinal pigment epithelium detachment. It is also developing ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P, which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma; and other angiogenic-related and inflammatory-oriented indications. In addition, the company develops Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical stage for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

25 Employees
Last Reported Date: 03/24/15

lpath inc-class a (LPTN) Top Compensated Officers

Interim Chief Executive Officer
Total Annual Compensation: $75.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $365.3K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $387.9K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $374.2K
Compensation as of Fiscal Year 2014.

lpath inc-class a (LPTN) Key Developments

Lpath Reports Results for iSONEP™ in Patients with Wet Age-related Macular Degeneration

Lpath Inc. announced that its multicenter, Phase 2 "Nexus" clinical trial evaluating iSONEP™ in patients with wet age-related macular degeneration (wet AMD) did not meet its primary or key secondary endpoints. Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea® did not show any statistically significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy. Nexus is a prospective, randomized, double-masked, positive control, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet AMD. All enrolled patients had been subresponsive to treatment with anti-VEGF drugs, and had received at least three previous injections of an anti-VEGF drug. Nexus study patients each received four intravitreal injections over the 90 day dosing period. There were approximately 39 patients in each of the four treatment arms. The pre-specified primary endpoint of the study was mean change in best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) from Day 0 to Day 120. At day 120, patients who received intravitreal injections of (i) 4.0 mg iSONEP alone lost a mean of 3.17 letters on the ETDRS, (ii) a combination of 0.5 mg iSONEP and anti-VEGF therapy gained a mean of 4.22 letters, (iii) a combination of 4.0 mg iSONEP and anti-VEGF therapy gained a mean of 3.63 letters, and (iv) an anti-VEGF therapy alone gained a mean of 4.34 letters. Full study results will be presented during the Retina Subspecialty Days in conjunction with the American Academy of Ophthalmology in Las Vegas, Nevada in November 2015.

Lpath Inc. - Shareholder/Analyst Call

To update investors on the progress of Lpath's programs

Lpath Inc. Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain

Lpath Inc. announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards. Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $0.28 USD -0.0027

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at